Resilience forges JV with MD Anderson, readying new cell therapies for cancer
The University of Texas MD Anderson Cancer Center and contract biologic manufacturer Resilience are cracking open a new partnership, seeking to accelerate the development and manufacturing of cell therapies for cancer patients.
The so-called Cell Therapy Manufacturing Center will be based in a 60,000-square-foot facility in downtown Houston. With a team of 70 employees, the center will focus on process and analytical development as well as early-phase and clinical-stage GMP.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.